TY - JOUR
T1 - Sodium glucose co-transporter 2 (SGLT2) inhibitors in heart failure with preserved ejection fraction: A systematic review and meta-analysis
AU - Tsampasian, Vasiliki
AU - Elghazaly, Hussein
AU - Chattopadhyay, Rahul Kumar
AU - Ali, Omar
AU - Corballis, Natasha
AU - Chousou, Panagiota Anna
AU - Clark, Allan
AU - Garg, Pankaj
AU - Vassiliou, Vassilios
N1 - Funding Information:
V.T., R.C., and N.C. are all supported by NIHR Academic Clinical Fellowships.
PY - 2022/4
Y1 - 2022/4
N2 - Whilst heart failure with preserved ejection fraction (HFpEF) is increasingly studied, the search for a single pharmacotherapeutic agent that will improve hard endpoints like hospitalization and mortality still continues.1 Given the various subphenotypes of HFpEF,2 this makes it difficult for a single agent to be universally beneficial. The recent publication of EMPEROR-PRESEVED3 was an instrumental time for an updated meta-analysis focused on sodium glucose co-transporter 2 inhibitors (SGLT2i) use in HFpEF.
AB - Whilst heart failure with preserved ejection fraction (HFpEF) is increasingly studied, the search for a single pharmacotherapeutic agent that will improve hard endpoints like hospitalization and mortality still continues.1 Given the various subphenotypes of HFpEF,2 this makes it difficult for a single agent to be universally beneficial. The recent publication of EMPEROR-PRESEVED3 was an instrumental time for an updated meta-analysis focused on sodium glucose co-transporter 2 inhibitors (SGLT2i) use in HFpEF.
UR - http://www.scopus.com/inward/record.url?scp=85129211578&partnerID=8YFLogxK
U2 - 10.1093/eurjpc/zwab189
DO - 10.1093/eurjpc/zwab189
M3 - Article
VL - 29
SP - e227–e229
JO - European Journal of Preventive Cardiology
JF - European Journal of Preventive Cardiology
SN - 2047-4873
IS - 6
ER -